T2 Biosystems Beheer

Beheer criteriumcontroles 3/4

De CEO T2 Biosystems is John Sperzel, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 865.50K, bestaande uit 66.4% salaris en 33.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde € 191.92. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 7.7 jaar.

Belangrijke informatie

John Sperzel

Algemeen directeur

US$865.5k

Totale compensatie

Percentage CEO-salaris	66.4%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.002%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is John Sperzel's beloning veranderd ten opzichte van T2 Biosystems's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$43m
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$866k	US$575k	-US$50m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$2m	US$575k	-US$62m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$563k	-US$49m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$3m	US$491k	-US$47m

Compensatie versus markt: De totale vergoeding ($USD 865.50K ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Sperzel (61 yo)

4.8yrs

Tenure

US$865,500

Compensatie

Mr. John J. Sperzel, III, B.Sc., serves as Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020 and has been its Chairman since July 23, 2021 and serves as President. Mr. Sperz...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Sperzel	President	4.8yrs	US$865.50k	0.0019% € 191.9
John Sprague	Chief Financial Officer	6.8yrs	US$581.00k	0.00069% € 67.9
Michael Gibbs	Senior VP	8.8yrs	US$622.60k	0.00066% € 65.0
Kelley Morgan	Chief People Officer	10.7yrs	geen gegevens	geen gegevens
Brett Giffin	Chief Commercial Officer	3yrs	geen gegevens	0.00037% € 36.4
Roger Smith	Senior Vice President of Science Research & Development	2.7yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 3T2 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Sperzel	President	4.8yrs	US$865.50k	0.0019% € 191.9
Robin Toft	Independent Director	4.4yrs	US$60.00k	0.00028% € 27.6
Seymour E. Liebman	Independent Director	8.2yrs	US$40.00k	0.00041% € 40.4
John Cumming	Lead Independent Director	10.3yrs	US$96.00k	0.00025% € 24.6
David Elsbree	Independent Director	10.3yrs	US$60.00k	0.00011% € 10.8
Eric Rosenberg	Member of Clinical Advisory Board	13.5yrs	geen gegevens	geen gegevens
Louis Rice	Member of Clinical Advisory Board	13.5yrs	geen gegevens	geen gegevens
Ninfa Saunders	Independent Director	4.4yrs	US$50.00k	0.00036% € 35.4
Peter Pappas	Member of Clinical Advisory Board	13.5yrs	geen gegevens	geen gegevens
Michael Pfaller	Member of Clinical Advisory Board	7.3yrs	US$1.10m	geen gegevens
Laura Adams	Independent Director	3.1yrs	US$40.00k	0.00021% € 20.7
Sean Zhang	Member of Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

72.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 3T2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

T2 Biosystems Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

Recent updates

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems Receives Letter from the Nasdaq Regarding Listing Rule 5550(b)(2)

T2 Biosystems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$12.15 loss per share (vs US$15.50 loss in FY 2021)

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Third quarter 2022 earnings released: US$2.95 loss per share (vs US$4.21 loss in 3Q 2021)

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022

T2 Biosystems Receives Non-Compliance Notice from Nasdaq

T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel

T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule

High number of new directors

First quarter 2022 earnings released: US$0.097 loss per share (vs US$0.072 loss in 1Q 2021)

T2 Biosystems Announces Receipt of Nasdaq Delisting Notice

High number of new directors

T2 Biosystems, Inc. Submits Application with U.S. Food and Drug Administration for Breakthrough Device Designation for T2Biothreat Panel

No longer forecast to breakeven

T2 Biosystems, Inc. to Report Q1, 2022 Results on May 05, 2022

T2 Biosystems, Inc. Announces Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat